Cover Image
市場調查報告書

重症肌無力:全球臨床實驗檢討

Myasthenia Gravis Global Clinical Trials Review, H1, 2018

出版商 GlobalData 商品編碼 223997
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
重症肌無力:全球臨床實驗檢討 Myasthenia Gravis Global Clinical Trials Review, H1, 2018
出版日期: 2018年03月30日 內容資訊: 英文 92 Pages
簡介

重症肌無力(MG)是慢性自體免疫神經肌肉疾病,依隨意肌肉無力的程度患者症狀也不同。重症肌無力是由於神經衝動對肌肉的傳達不良,造成肌肉結點神經和肌肉之間正常的通訊被中斷所引起。主要常見於40歲以下的成年女性或60歲以上男性。症狀有呼吸困難、吞嚥障礙、理解障礙、難以爬上樓梯、舉起物品、從座位上站起身來、眼瞼下垂·臉部肌肉降低/麻痺、疲勞、嘶啞聲音/聲音的變化、複視/視力模糊等。

本報告提供重症肌無力相關臨床研究最新趨勢相關分析,提供您疾病·治療方法概要,及G7各國的臨床實驗狀況,各地區、各階段(Phase)的進行狀況,有潛力的贊助商,並彙整各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

簡介

  • 重症肌無力
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 主要國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量: 重症肌無力臨床實驗數量上免疫學臨床實驗數量比率

Phase別臨床實驗數量: G7各國

G7各國的臨床實驗數量:Phase別

E7各國的臨床實驗數量: 重症肌無力臨床實驗數量上免疫學臨床實驗數量比率

Phase別臨床實驗數量: E7各國

E7各國的臨床實驗數量:Phase別

Phase別臨床實驗數量

  • Phase別的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

未完成的臨床實驗

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 重症肌無力治療藥

有潛力的藥劑

臨床實驗簡介

  • 有代表性的企業臨床實驗概要
    • F. Hoffmann-La Roche Ltd.
    • Cytokinetics, Inc.
    • Astellas Pharma Inc.
    • Alexion Pharmaceuticals, Inc.
    • Volution Immuno Pharmaceuticals (VIP) SA
    • Grifols, S.A.
    • GlaxoSmithKline plc
    • Bayhill Therapeutics, Inc.
    • AstraZeneca PLC
    • Amarin Corporation plc
  • 有代表性的研究機關/醫院臨床實驗概要
    • Sun Yat-sen University
    • University Health Network
    • Leiden University Medical Center
    • Assistance Publique - Hopitaux de Paris
    • Yale University
    • Toronto General Hospital
    • FDA Office of Orphan Products Development
    • The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
    • Indiana University
    • Fred Hutchinson Cancer Research Center

5大臨床實驗簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4827CTIDB

GlobalData's clinical trial report, "Myasthenia Gravis Global Clinical Trials Review, H1, 2018" provides an overview of Myasthenia Gravis clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Myasthenia Gravis to Immunology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Myasthenia Gravis to Immunology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Myasthenia Gravis Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Myasthenia Gravis 30
  • Jan 09, 2018: GT Biopharma Announces Completion of Dosing in Phase I Clinical Trial of GTP-004 for Myasthenia Gravis 30
  • Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment 30
  • Dec 21, 2017: Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients 31
  • Dec 11, 2017: argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis 31
  • Dec 06, 2017: GT Biopharma Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease 32
  • Clinical Trial Profile Snapshots 33

Appendix 89

  • Abbreviations 89
  • Definitions 89
  • Research Methodology 90
  • Secondary Research 90
  • About GlobalData 91
  • Contact Us 91
  • Source 91

List of Tables

List of Tables

  • Myasthenia Gravis Therapeutics, Global, Clinical Trials by Region, 2018* 7
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
  • Myasthenia Gravis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 10
  • Myasthenia Gravis Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 11
  • Myasthenia Gravis Therapeutics Clinical Trials, North America, Top Countries, 2018* 12
  • Myasthenia Gravis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 13
  • Myasthenia Gravis Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 14
  • Proportion of Myasthenia Gravis to Immunology Clinical Trials, G7 Countries (%), 2018* 15
  • Myasthenia Gravis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
  • Myasthenia Gravis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
  • Proportion of Myasthenia Gravis to Immunology Clinical Trials, E7 Countries (%), 2018* 18
  • Myasthenia Gravis Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
  • Myasthenia Gravis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials by Phase, 2018* 21
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 22
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25
  • Myasthenia Gravis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 26
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29

List of Figures

List of Figures

  • Myasthenia Gravis Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
  • Myasthenia Gravis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 10
  • Myasthenia Gravis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 11
  • Myasthenia Gravis Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 12
  • Myasthenia Gravis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 13
  • Myasthenia Gravis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 14
  • Proportion of Myasthenia Gravis to Immunology Clinical Trials, G7 Countries (%), 2018* 15
  • Myasthenia Gravis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
  • Myasthenia Gravis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
  • Proportion of Myasthenia Gravis to Immunology Clinical Trials, E7 Countries (%), 2018* 18
  • Myasthenia Gravis Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
  • Myasthenia Gravis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials by Phase (%), 2018* 21
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 22
  • Myasthenia Gravis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25
  • Myasthenia Gravis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 26
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28
  • Myasthenia Gravis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29
  • GlobalData Methodology 90
Back to Top